×
About 32,648 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  15,861 results

The cumulative incidence of dysphagia and dysphagia-free survival in persons diagnosed ...
https://doi.org/10.1002/mus.27244
Muscle & Nerve; Perry BJ, Nelson J et. al.

Apr 14th, 2021 - Dysphagia worsens mortality and quality of life for persons diagnosed with amyotrophic lateral sclerosis (ALS), yet our understanding of its incidence and timing remains limited. We sought to estimate dysphagia incidence and dysphagia-free surviva...

Identification of Rpd3 as a novel epigenetic regulator of Drosophila FIG 4, a Charcot-M...
https://doi.org/10.1097/WNR.0000000000001636
Neuroreport Muraoka Y, Nikaido A et. al.

Apr 14th, 2021 - Mutations in the factor-induced-gene 4 (FIG 4) gene are associated with multiple disorders, including Charcot-Marie-Tooth disease (CMT), epilepsy with polymicrogyria, Yunis-Varón syndrome and amyotrophic lateral sclerosis. The wide spectrum of dis...

Stapedial Reflex: A Possible Novel Biomarker of Early Bulbar Involvement in Amyotrophic...
https://doi.org/10.1159/000513482
Audiology & Neuro-otology; Bombaci A, Lazzaro C et. al.

Apr 13th, 2021 - Amyotrophic lateral sclerosis (ALS) is a neuromuscular progressive disorder, characterized by limb and bulbar muscle wasting and weakness. 30% of patients present a bulbar onset, while 70% a spinal outbreak, although most of them develop bulbar im...

Gene Therapy for ALS: A Review.
https://doi.org/10.1016/j.ymthe.2021.04.008
Molecular Therapy : the Journal of the American Society O... Amado DA, Davidson BL

Apr 11th, 2021 - Amyotrophic lateral sclerosis (ALS) has historically posed unique challenges for gene therapy-based approaches, due to a paucity of therapeutic targets as well as the difficulty of accessing both the brain and spinal cord. Recent advances in our u...

see more →

Guidelines  9 results

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

MDA U.S. Neuromuscular Disease Registry
https://www.mda.org/services/neuromuscular-disease-registry
Muscular Dystrophy Association (USA)

Dec 31st, 2015 - In 2013, MDA launched the U. S.

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--rev...
https://doi.org/10.1111/j.1468-1331.2011.03501.x
European Journal of Neurology; , Andersen PM et. al.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  16,271 results

The cumulative incidence of dysphagia and dysphagia-free survival in persons diagnosed ...
https://doi.org/10.1002/mus.27244
Muscle & Nerve; Perry BJ, Nelson J et. al.

Apr 14th, 2021 - Dysphagia worsens mortality and quality of life for persons diagnosed with amyotrophic lateral sclerosis (ALS), yet our understanding of its incidence and timing remains limited. We sought to estimate dysphagia incidence and dysphagia-free surviva...

Identification of Rpd3 as a novel epigenetic regulator of Drosophila FIG 4, a Charcot-M...
https://doi.org/10.1097/WNR.0000000000001636
Neuroreport Muraoka Y, Nikaido A et. al.

Apr 14th, 2021 - Mutations in the factor-induced-gene 4 (FIG 4) gene are associated with multiple disorders, including Charcot-Marie-Tooth disease (CMT), epilepsy with polymicrogyria, Yunis-Varón syndrome and amyotrophic lateral sclerosis. The wide spectrum of dis...

Stapedial Reflex: A Possible Novel Biomarker of Early Bulbar Involvement in Amyotrophic...
https://doi.org/10.1159/000513482
Audiology & Neuro-otology; Bombaci A, Lazzaro C et. al.

Apr 13th, 2021 - Amyotrophic lateral sclerosis (ALS) is a neuromuscular progressive disorder, characterized by limb and bulbar muscle wasting and weakness. 30% of patients present a bulbar onset, while 70% a spinal outbreak, although most of them develop bulbar im...

Gene Therapy for ALS: A Review.
https://doi.org/10.1016/j.ymthe.2021.04.008
Molecular Therapy : the Journal of the American Society O... Amado DA, Davidson BL

Apr 11th, 2021 - Amyotrophic lateral sclerosis (ALS) has historically posed unique challenges for gene therapy-based approaches, due to a paucity of therapeutic targets as well as the difficulty of accessing both the brain and spinal cord. Recent advances in our u...

see more →

News  457 results

Theatrics, Hypnosis, and the Roots of Modern Neurology
https://www.medscape.com/viewarticle/947504

Mar 14th, 2021 - "Symptoms, then, are in reality nothing but a cry from suffering organs" – Jean-Martin Charcot Nearly 130 years after his death, Jean-Martin Charcot's name still resonates with modern neurologists. The famed 19th century French physician made myri...

New Compound Promising for ALS, Other Upper Motor Neuron Diseases
https://www.medscape.com/viewarticle/947056

Mar 10th, 2021 - NEW YORK (Reuters Health) - A new compound, NU-9, improved diseased upper motor neurons (UMN) in mice and shows promise for treating amyotrophic lateral sclerosis (ALS) in humans, though more work is needed before a clinical trial can be started, ...

After a Decade of Lobbying, ALS Patients Gain Faster Access to Disability Payments
https://www.medscape.com/viewarticle/944474

Jan 20th, 2021 - Anita Baron first noticed something was wrong in August 2018, when she began to drool. Her dentist chalked it up to a problem with her jaw. Then her speech became slurred. She managed to keep her company, which offers financing to small businesses...

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.staging.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

see more →

Patient Education  19 results see all →